Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Declan Doogan sold 121,942 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $26.78, for a total transaction of $3,265,606.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Declan Doogan also recently made the following trade(s):
- On Wednesday, January 10th, Declan Doogan sold 40,362 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $27.69, for a total transaction of $1,117,623.78.
Biohaven Pharmaceutical Holding Co Ltd (BHVN) opened at $26.44 on Friday. Biohaven Pharmaceutical Holding Co Ltd has a 52-week low of $17.00 and a 52-week high of $39.51. The stock has a market cap of $1,100.00 and a price-to-earnings ratio of -5.07.
BHVN has been the topic of a number of recent analyst reports. Morgan Stanley reissued an “overweight” rating and issued a $38.00 price target (down previously from $47.00) on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 3rd. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Monday, December 4th. Piper Jaffray Companies set a $48.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Monday, December 11th. Needham & Company LLC dropped their price target on shares of Biohaven Pharmaceutical from $43.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, October 3rd. Finally, Canaccord Genuity initiated coverage on shares of Biohaven Pharmaceutical in a research report on Friday, December 15th. They issued a “buy” rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $36.14.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.